Pharmaceutical Product Development, LLC (PPD) has entered into a collaboration with Frenova Renal Research, a drug and medical device clinical development services provider dedicated to renal research.

As part of Fresenius Medical Care North America (FMCNA), Frenova’s network of resources encompasses 260 research sites with 450 principal investigators and access to more than 183,000 active ESRD patients and 390,000 active CKD patients. Frenova’s data access gathers and analyzes large amounts of patient data from within the company’s own care ecosystem.  

PPD will offer Frenova’s global nephrology expertise, as well as access to F1RST Up (Frenova Rapid STart Up), Frenova’s exclusive alliance of research sites designed to streamline, initiate and enroll clinical studies faster than industry norms with just-in-time patient recruitment.

“The opportunity to collaborate with Frenova enhances our ability to connect our clients with researchers recognized as world leaders in the field of nephrology and further strengthens our industry-leading global site and patient capabilities by helping to deliver seamless access to patients, sites and data sources,” said Ulrich Zoeller, vice president, project management, general medicine for PPD. “Frenova’s access to more than two-thirds of all U.S. nephrology patients, coupled with the breadth of its resources and experience in renal research, will enable PPD to continue to build on its already strong presence in nephrology trials.”

 “Our collaboration with PPD expands the reach of our nephrology experts and broadens the impact of our invaluable treatment data in clinical trials,” said Kurt Mussina, general manager, Frenova. “We are pleased to join forces with PPD through our shared commitment of improving the lives of patients living with kidney disease, around the world, through the advancement of renal research.”